Longeveron Inc. Material Event - Nasdaq Compliance Update

This guide explains the latest news from Longeveron Inc. (Nasdaq: LGVN) in plain English. Longeveron is a biotech company developing cell therapies for aging-related and life-threatening conditions.

1. What happened?

Nasdaq has granted Longeveron a second 180-day extension to meet its minimum price rules. To remain listed on the Nasdaq Capital Market, the company’s stock must close at or above $1.00 per share.

2. When did it happen?

Longeveron received the official notification from Nasdaq on March 24, 2026.

3. Why did it happen?

Nasdaq requires listed stocks to trade at $1.00 or higher for 30 consecutive business days. Longeveron was unable to meet this target during its first 180-day grace period, which ended March 23, 2026. The company qualified for this second chance by meeting other financial criteria, such as maintaining at least $5 million in shareholder equity.

4. Why does this matter?

This extension acts as a "stay of execution" for Longeveron’s spot on the exchange. If the company is delisted, the stock would move to the "Pink Sheets" (Over-the-Counter market). This market typically has lower trading volume, fewer institutional investors, and wider price gaps, which can make it more difficult and costlier to trade. The company now has until September 21, 2026, to resolve the price deficiency.

5. Who is affected?

• Investors: You retain the benefits of trading on a major exchange for now. However, the low share price reflects market concerns regarding the company’s cash reserves and the long-term development timeline for its lead product, Lomecel-B.
• Patients: This is an administrative update. It does not impact ongoing clinical trials for conditions like Alzheimer’s or heart defects.
• The Company: Avoiding delisting helps Longeveron maintain its reputation and avoids the significant fundraising hurdles that often follow a move to the Pink Sheets.

6. What happens next?

To regain compliance, the stock must close at $1.00 or higher for at least ten consecutive business days before September 21, 2026. If the price does not rise naturally, the company may opt for a "reverse stock split." This process combines existing shares into fewer, higher-priced shares to mathematically meet the $1.00 requirement.

7. What should investors know?

• The Clock is Ticking: If the company fails to meet the requirement by the September deadline, it will face a formal delisting notice. While the company could appeal to a Nasdaq panel, there is no guarantee of success.
• Watch for Volatility: Markets often react negatively to reverse stock splits, as they can signal that management is concerned the stock price will not rise on its own.
• Focus on Fundamentals: Longeveron is a biotech company currently spending more cash than it earns. When evaluating your position, prioritize the company’s cash burn rate and upcoming clinical trial results. These operational milestones—rather than artificial share consolidation—are the primary drivers that could sustainably increase the stock price.

Disclaimer: I am an AI, not a financial advisor. This summary is for information only and is not financial or investment advice. Always do your own research before making investment decisions.